Table 2.
Association between desloratadine (DL) exposure and first seizure
| DL exposure | Number (N) | Follow-up time (PY) | Unadjusted | Adjusteda | ||||
|---|---|---|---|---|---|---|---|---|
| IR per 100,000 PY | IRR | 95% CI | IR per 100,000 PY | IRR | 95% CI | |||
| Yes | 745 | 1,166,122 | 63.9 | 1.61 | (1.49–1.75) | 31.6 | 1.46 | (1.34–1.59) |
| No | 2,627 | 6,634,828 | 39.6 | 1 | Ref. | 21.7 | 1 | Ref. |
| Stratified by country | ||||||||
| Denmark | ||||||||
| Yes | 129 | 133,806 | 96.4 | 2.38 | (1.96–2.89) | 42.3 | 1.75 | (1.44–2.14) |
| No | 503 | 1,242,345 | 40.5 | 1 | Ref. | 24.2 | 1 | Ref. |
| Finland | ||||||||
| Yes | 151 | 325,951 | 46.3 | 1.67 | (1.40–1.98) | 34.8 | 1.44 | (1.20–1.73) |
| No | 711 | 2,555,545 | 27.8 | 1 | Ref. | 24.1 | 1 | Ref. |
| Norway | ||||||||
| Yes | 57 | 173,685 | 32.8 | 1.85 | (1.29–2.65) | 13.0 | 1.98 | (1.36–2.89) |
| No | 61 | 343,630 | 17.8 | 1 | Ref. | 6.5 | 1 | Ref. |
| Sweden | ||||||||
| Yes | 408 | 532,679 | 76.6 | 1.41 | (1.26–1.58) | 47.6 | 1.34 | (1.19–1.50) |
| No | 1,352 | 2,493,308 | 54.2 | 1 | Ref. | 35.7 | 1 | Ref. |
| Stratified by age | ||||||||
| 0–5 years | ||||||||
| Yes | 436 | 122,811 | 355.0 | 1.89 | (1.69–2.11) | 270.8 | 1.85 | (1.65–2.08) |
| No | 1,012 | 538,445 | 187.9 | 1 | Ref. | 146.5 | 1 | Ref. |
| 6–19 years | ||||||||
| Yes | 143 | 270,274 | 52.9 | 1.36 | (1.14–1.63) | 36.3 | 1.42 | (1.17–1.71) |
| No | 655 | 1,685,810 | 38.9 | 1 | Ref. | 25.6 | 1 | Ref. |
| ≥ 20 years | ||||||||
| Yes | 166 | 773,038 | 21.5 | 0.99 | (0.84–1.16) | 11.9 | 1.01 | (0.85–1.19) |
| No | 960 | 4,410,573 | 21.8 | 1 | Ref. | 11.8 | 1 | Ref. |
Values are expressed as numbers (N), follow-up time in PY, IR per 100,000 PY, and IRR with corresponding 95% CI for the unadjusted and adjusted analyses
CI confidence interval, IR incidence rate, IRR incidence rate ratio, PY person-years
a Adjusted for age (5-year age categories), sex, country, calendar year (1-year categories), seasonality, asthma, severe rhinitis, and chronic urticaria